NanoString Technologies Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NanoString Technologies stock.
View analyst ratings for NanoString Technologies or view top-rated stocks.

Wall Street analysts have given NanoString Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NanoString Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

NanoString Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for NanoString Technologies.

NanoString Technologies will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 416-621-4642 with passcode "3414117".

NanoString Technologies, Inc. (NASDAQ:NSTG) posted its earnings results on Monday, May, 10th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.04. The biotechnology company had revenue of $31.60 million for the quarter, compared to analyst estimates of $30.51 million. NanoString Technologies had a negative net margin of 81.07% and a negative trailing twelve-month return on equity of 52.15%. The firm's revenue for the quarter was up 18.8% on a year-over-year basis.
View NanoString Technologies' earnings history.

NanoString Technologies' stock was trading at $30.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NSTG shares have increased by 103.5% and is now trading at $62.08.
View which stocks have been most impacted by COVID-19.

5 analysts have issued 12-month price targets for NanoString Technologies' stock. Their forecasts range from $40.00 to $80.00. On average, they expect NanoString Technologies' share price to reach $67.60 in the next year. This suggests a possible upside of 8.9% from the stock's current price.
View analysts' price targets for NanoString Technologies or view top-rated stocks among Wall Street analysts.

36 employees have rated NanoString Technologies CEO Brad Gray on Glassdoor.com. Brad Gray has an approval rating of 65% among NanoString Technologies' employees.

Some companies that are related to NanoString Technologies include CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), Exelixis (EXEL), Adaptive Biotechnologies (ADPT), Vir Biotechnology (VIR), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX) and Abcam (ABCM).
View all of NSTG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank of the Ozarks (OZRK) and Vista Outdoor (VSTO).

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.01%). Company insiders that own NanoString Technologies stock include Charles P Waite Jr, Charles P Waite, Jr, David W Ghesquiere, Elisha W Finney, Gregory Norden, J Chad Brown, Joseph M Beechem, K Thomas Bailey, Kirk Malloy, R Bradley Gray, Robert Hershberg and William Young.
View institutional ownership trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold NanoString Technologies company stock in the last year include Charles P Waite Jr, Elisha W Finney, Gregory Norden, J Chad Brown, Joseph M Beechem, K Thomas Bailey, Kirk Malloy, R Bradley Gray, and Robert Hershberg.
View insider buying and selling activity for NanoString Technologies or view top insider-selling stocks.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NSTG stock can currently be purchased for approximately $62.08.

NanoString Technologies has a market capitalization of $2.81 billion and generates $117.32 million in revenue each year. The biotechnology company earns $-110,080,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

NanoString Technologies employs 579 workers across the globe.

The official website for NanoString Technologies is www.nanostring.com.

NanoString Technologies is headquartered at 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at (888) 358-6266 or via email at [email protected]